Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Kodama H, et al. Among authors: omori s. Cancer Med. 2021 Nov;10(21):7503-7513. doi: 10.1002/cam4.4268. Epub 2021 Sep 29. Cancer Med. 2021. PMID: 34587359 Free PMC article.
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Ko R, Kenmotsu H, Hisamatsu Y, Akamatsu H, Omori S, Nakashima K, Oyakawa T, Wakuda K, Shukuya T, Ono A, Imai H, Taira T, Naito T, Murakami H, Mori K, Endo M, Ohde Y, Takahashi K, Takahashi T. Ko R, et al. Among authors: omori s. Int J Clin Oncol. 2015 Aug;20(4):668-73. doi: 10.1007/s10147-014-0761-8. Epub 2014 Oct 25. Int J Clin Oncol. 2015. PMID: 25343946
Doublet chemotherapy with cisplatin and pemetrexed is associated with a favorable outcome in patients with advanced non-squamous non-small-cell lung cancer who are eligible for bevacizumab and maintenance therapy.
Nakashima K, Murakami H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Endo M, Takahashi T. Nakashima K, et al. Among authors: omori s. Mol Clin Oncol. 2016 Nov;5(5):575-578. doi: 10.3892/mco.2016.1001. Epub 2016 Aug 24. Mol Clin Oncol. 2016. PMID: 27900087 Free PMC article.
Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N, Kenmotsu H, Serizawa M, Umehara R, Ono A, Hisamatsu Y, Wakuda K, Omori S, Nakashima K, Taira T, Naito T, Murakami H, Koh Y, Mori K, Endo M, Nakajima T, Yamada M, Kusuhara M, Takahashi T. Kasahara N, et al. Among authors: omori s. Lung Cancer. 2017 Apr;106:138-144. doi: 10.1016/j.lungcan.2017.02.001. Epub 2017 Feb 4. Lung Cancer. 2017. PMID: 28285688
The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
Fujiwara T, Kenmotsu H, Naito T, Kawamura T, Mamesaya N, Kotake M, Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Taira T, Murakami H, Omae K, Mori K, Endo M, Takahashi T. Fujiwara T, et al. Among authors: omori s. Cancer Chemother Pharmacol. 2017 Jun;79(6):1229-1237. doi: 10.1007/s00280-017-3324-7. Epub 2017 Apr 28. Cancer Chemother Pharmacol. 2017. PMID: 28455585
Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma.
Kasahara N, Wakuda K, Omori S, Nakashima K, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Mori K, Watanabe R, Endo M, Nakajima T, Yamada M, Takahashi T. Kasahara N, et al. Among authors: omori s. Mol Clin Oncol. 2017 May;6(5):718-722. doi: 10.3892/mco.2017.1198. Epub 2017 Mar 17. Mol Clin Oncol. 2017. PMID: 28529747 Free PMC article.
392 results